400 Pleasant Street
United States - Map
pSivida Corp., together with its subsidiaries, develops drug delivery products for treatment of back-of-the-eye diseases that are administered by implantation, injection, or insertion. The company focuses on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert and BioSilicon. Its two FDA-approved products utilizing its Durasert technology system include Retisert for the treatment of posterior uveitis and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. The company holds license to market ILUVIEN, the injectable, sustained release micro-insert for the treatment of chronic diabetic macular edema (DME) in Austria, France, Germany, Portugal, and the United Kingdom; and has completed two Phase III clinical trials for the treatment of vision impairment associated with chronic DME. In addition, it is conducting investigator-sponsored pilot clinical trials with ILUVIEN for the treatment of wet and dry form of age-related macular degeneration, and retinal vein occlusion. Further, the company engages in developing the Latanoprost product, an injectable, bioerodible drug delivery micro-insert, which is in investigator-sponsored Phase I/II clinical trials for the treatment of glaucoma and ocular hypertension; the Posterior Uveitis product candidate in a Phase I/II dose-ranging study for the treatment of posterior uveitis; BioSilicon technology system, which utilizes a honeycomb structure of nano-porous, elemental silicon to provide sustained delivery of therapeutics; and Tethadur that utilizes BioSilicon technology to deliver large biologic molecules, including peptides and proteins. It has strategic collaborations with Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.
|Dr. Paul Ashton B.Sc., Ph.D.,
Chief Exec. Officer, Pres and Exec. Director
|Mr. Leonard S. Ross ,
Principal Financial & Accounting Officer and VP of Fin.
|Ms. Lori H. Freedman Esq., B.A., J.D.,
VP of Corp. Affairs, Gen. Counsel and Sec.
|Mr. Marty Nazzaro ,
VP of Operations
|Mr. Brian Leedman B.Econ., M.B.A.,
VP of Investor Relations
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|